Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges (2014 - 2026)
Ligand Pharmaceuticals (LGND) reported Amortization of Deferred Charges of $803000.0 for Q1 2026, up 490.44% on a YoY basis from $136000.0 in Q1 2025, and up 42.12% sequentially from $565000.0 in Q4 2025.
Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 13 years of Amortization of Deferred Charges data on file, last reported at $803000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 490.44% year-over-year to $803000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 251.86% YoY), and the FY2025 full-year result was $1.3 million, up 161.93% from the prior year.
- Amortization of Deferred Charges improved to $803000.0 in Q1 2026, from $565000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $803000.0 in Q1 2026 to a low of $81000.0 in Q4 2023.
- A 5-year average of $219500.0 and a median of $129500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges slumped 97.52% in 2022 and soared 490.44% in 2026, its largest moves.
- Tracing LGND's Amortization of Deferred Charges over 5 years: stood at $95000.0 in 2022, then dropped by 14.74% to $81000.0 in 2023, then jumped by 112.35% to $172000.0 in 2024, then jumped by 228.49% to $565000.0 in 2025, then surged by 42.12% to $803000.0 in 2026.
- Business Quant data shows LGND's Amortization of Deferred Charges at $803000.0 in Q1 2026, $565000.0 in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.96 Bn | 5.18 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 803,000.00 |
| Mar 31, 2026 | 803,000.00 |
| Dec 31, 2025 | 565,000.00 |
| Dec 31, 2025 | 565,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Mar 31, 2025 | 136,000.00 |
| Mar 31, 2025 | 136,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Sep 30, 2024 | 134,000.00 |
| Sep 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Dec 31, 2023 | 81,000.00 |